Cipher Pharmaceuticals Inc. (FRA:PHE)
Germany · Delayed Price · Currency is EUR | Market Cap | 217.28M -3.5% |
| Revenue (ttm) | 43.44M +4.3% |
| Net Income | 25.37M +138.7% |
| EPS | 1.01 +140.9% |
| Shares Out | n/a |
| PE Ratio | 8.13 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Open | 8.25 |
| Previous Close | 7.95 |
| Day's Range | 8.25 - 8.50 |
| 52-Week Range | 7.00 - 12.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage... [Read more]
Financial Performance
In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.
Financial numbers in USD Financial StatementsNews
Cipher Pharmaceuticals price target lowered to C$20 from C$22 at Stifel
Stifel analyst Justin Keywood lowered the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$20 from C$22 and keeps a Buy rating on the shares.
Cipher Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw a 10% revenue decline due to lower U.S. Natroba sales, but strong Canadian Epuris growth and cost efficiencies maintained high profitability, with adjusted EBITDA margins at 57%. Expanded public drug plan coverage for Epuris and new U.S. retail initiatives are expected to drive future growth.
Cipher Pharmaceuticals Earnings release: Q2 2026
Cipher Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Cipher Pharmaceuticals MD&A: Q2 2026
Cipher Pharmaceuticals filed a regulatory document on August 12, 2026 disclosing important business information.
Cipher Pharmaceuticals Report: Q2 2026
Cipher Pharmaceuticals published a report on August 12, 2026 containing material business information for investors and shareholders.
Cipher Pharmaceuticals price target raised to C$22 from C$21 at Stifel
Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$22 from C$21 and keeps a Buy rating on the shares.
Cipher Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% revenue growth, 25% higher adjusted EBITDA, and a 138% increase in net income year-over-year, driven by strong U.S. Natroba performance and improved margins. Full debt repayment and a renewed share buyback highlight robust cash flow and disciplined capital allocation.
Cipher Pharmaceuticals Slides: Q1 2026
Cipher Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Cipher Pharmaceuticals Earnings release: Q1 2026
Cipher Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Cipher Pharmaceuticals Report: Q1 2026
Cipher Pharmaceuticals published a report on May 8, 2026 containing material business information for investors and shareholders.
Cipher Pharmaceuticals MD&A: Q1 2026
Cipher Pharmaceuticals filed a regulatory document on May 8, 2026 disclosing important business information.
CaryHealth launches direct-to-patient program for Cipher’s Natroba
CaryHealth announced the launch of its direct-to-patient platform to support seamless access to Natroba, a prescription treatment for head lice and scabies, in partnership with Cipher Pharmaceuticals ...
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)
WASHINGTON--(BUSINESS WIRE)-- #DTP--CaryHealth, a leading digital health company, today announced the launch of its direct-to-patient (DTP) platform to support seamless access to Natroba (spinosad), a...
Cipher Pharmaceuticals price target raised to C$21 from C$20 at Stifel
Stifel raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$21 from C$20 and keeps a Buy rating on the shares.
Cipher Pharmaceuticals Earnings Call Transcript: Q4 2025
Revenue and earnings more than doubled in 2025, driven by Natroba's strong US performance and a stable Canadian base. The new DTC platform and upcoming Canadian launch are expected to fuel further growth, while licensing revenue faces pressure from generics.
Cipher Pharmaceuticals Earnings release: Q4 2025
Cipher Pharmaceuticals released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Cipher Pharmaceuticals MD&A: Q4 2025
Cipher Pharmaceuticals filed a regulatory document on March 13, 2026 disclosing important business information.
Cipher Pharmaceuticals Report: Q4 2025
Cipher Pharmaceuticals published a report on March 13, 2026 containing material business information for investors and shareholders.
Cipher Pharmaceuticals Annual report: Q4 2025
Cipher Pharmaceuticals has published its Q4 2025 annual report on March 13, 2026.
Cipher Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and profit growth, led by Natroba, with significant debt reduction and robust free cash flow. Licensing revenue declined due to generic competition, but new DTC and global expansion strategies are underway. Several state Medicaid bids for Natroba are pending.
Cipher Pharmaceuticals Earnings release: Q3 2025
Cipher Pharmaceuticals released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Cipher Pharmaceuticals Slides: Q3 2025
Cipher Pharmaceuticals has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.
Cipher Pharmaceuticals MD&A: Q3 2025
Cipher Pharmaceuticals filed a regulatory document on November 7, 2025 disclosing important business information.
Cipher Pharmaceuticals Report: Q3 2025
Cipher Pharmaceuticals published a report on November 7, 2025 containing material business information for investors and shareholders.
Cipher Pharmaceuticals price target raised to C$20 from C$17 at Stifel
Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$20 from C$17 and keeps a Buy rating on the shares.